Richard was invited to speak at the CBI.net industry conference identified as Expanded Access Programs to discuss the issue of Patient Perspective on Compassionate Use and Early Access to Life-Transforming Treatment.
In July, 2012, President Obama signed into law the Creating Hope Act for the purpose of incentivizing pharmaceutical companies, biotech firms and universities in seeking cures for what are known as Rare Children’s Diseases. Childhood Cancer is considered such a Rare Children’s Disease. Companies that are successful receiving approval from the FDA of drugs that meet the criteria of the Act receive vouchers that can be valuable to the companies in their efforts to bring other drugs to the market or, if they wish, can result in the sales of the vouchers by the companies to other companies at substantial prices. On March 10, 2015 a new drug specifically for children, aimed at high-risk neuroblastoma received FDA approval thanks to the Creating Hope Act.
March 12, 2015, demonstrated better than any other example the “highs and lows” experienced by those of us in the childhood cancer community seeking to make a difference for children with cancer and their families.
Max Cure Foundation's Vice-Chairman, Richard Plotkin calls upon the Congressional Caucus, led by Congressmen McCaul and Van Hollen, to do whatever is necessary through the Department of Homeland Security and/or the FBI to immediately begin an investigation to catch those that continue to prey on families facing the nightmare of having a child with cancer, and then, having experienced the death of that child.
Max Cure Foundations Vice-Chairman, Richard Plotkin adds to the Dana-Farber Cancer Institute's recent webchat on survivorship in childhood cancer. In this post you will find the video where Lisa Diller, MD, answers questions about the unique needs and concerns for patients and families transitioning off treatment, including fertility issues, follow-up care, and emotional challenges young survivors face.